Form 4: Tevogen Bio Holdings Grants 200,000 Restricted Shares to Chief Commercial Officer Sadiq Khan

Tevogen Bio Holdings Inc. has granted 200,000 restricted shares of common stock to Chief Commercial Officer Sadiq Khan, vesting in three equal annual installments starting June 27, 2030.

Summary

• Sadiq Khan, Chief Commercial Officer of Tevogen Bio Holdings Inc. (TVGN), was granted 200,000 shares of common stock.
• The shares were acquired on June 27, 2025, at a price of $0 per share, indicating a restricted stock grant.
• Following this transaction, Sadiq Khan beneficially owns 1,169,618 shares of Tevogen Bio Holdings Inc. common stock.
• This grant is part of the Tevogen Bio Holdings Inc. 2024 Omnibus Incentive Plan.
• The restricted stock will vest ratably in three equal annual installments, with the first vesting date commencing on June 27, 2030.
• Vesting is contingent upon Sadiq Khan remaining in service with Tevogen Bio Holdings Inc. at the specified vesting dates.

Sentiment

Score: 7

Explanation: The grant of restricted stock to a key officer is generally a positive signal, indicating management retention and alignment with long-term company performance. The very long vesting period (starting 2030) introduces some uncertainty but also signifies a long-term commitment.

Positives

• Aligns the Chief Commercial Officer's interests with long-term shareholder value through equity ownership.
• Incentivizes retention of key management personnel due to the service-based vesting condition.
• Demonstrates the company's commitment to its 2024 Omnibus Incentive Plan for employee motivation.

Negatives

• The vesting period is exceptionally long, with the first installment not commencing until June 27, 2030, which is five years after the grant date.
• The value of the grant is contingent on the future stock price of Tevogen Bio Holdings Inc., introducing market risk for the recipient.

Risks

• Risk of forfeiture if the reporting person does not remain in service with the Issuer until the vesting dates.
• Market risk associated with the future value of the common stock upon vesting.

Future Outlook

The restricted stock grant is designed to incentivize long-term service and performance, with vesting scheduled to begin in 2030, contingent on the Chief Commercial Officer's continued employment.

Industry Context

This transaction is a standard practice in the biotechnology and pharmaceutical industries, where equity compensation, particularly restricted stock, is commonly used to attract, retain, and motivate key executives and align their interests with long-term company performance and shareholder value creation.

Related Party Transactions

• The grant of 200,000 restricted shares to Sadiq Khan, Chief Commercial Officer, constitutes a related party transaction as it involves compensation to a key executive.

Stakeholder Impact

• Shareholders: Potential positive impact through improved management retention and alignment of executive interests with long-term company performance.
• Employees: May signal the company's commitment to equity-based incentive plans for key personnel.

Next Steps

• Continued service of Sadiq Khan with Tevogen Bio Holdings Inc. to meet vesting conditions.
• Future annual vesting events for the restricted stock grant commencing June 27, 2030.

Key Dates

Keywords

Tevogen Bio Holdings Inc., TVGN, Sadiq Khan, Chief Commercial Officer, Restricted Stock Grant, Equity Compensation, SEC Form 4, Insider Transaction, Omnibus Incentive Plan, Stock Vesting